Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
000 patients were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings support the integration of TARE into multidisciplinary management strategies for advanced HCC, particularly in patients unsuitable for surgical or systemic therapies. [SYSTEMATIC REVIEW REGISTRATION] PROSPERO (CRD420251163947).
[BACKGROUND] Transarterial radioembolization (TARE) using Yttrium-90 microspheres has emerged as a promising locoregional therapy for patients with advanced hepatocellular carcinoma (HCC).
- 95% CI 0.63-0.83
- OR 0.74
- HR 0.72
- 연구 설계 meta-analysis
APA
Lin H, Tan Q (2026). Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.. Frontiers in nuclear medicine, 6, 1784215. https://doi.org/10.3389/fnume.2026.1784215
MLA
Lin H, et al.. "Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.." Frontiers in nuclear medicine, vol. 6, 2026, pp. 1784215.
PMID
41938734 ↗
Abstract 한글 요약
[BACKGROUND] Transarterial radioembolization (TARE) using Yttrium-90 microspheres has emerged as a promising locoregional therapy for patients with advanced hepatocellular carcinoma (HCC). However, the efficacy and safety of TARE compared to conventional treatments remain uncertain. This meta-analysis aimed to comprehensively evaluate the survival outcomes and safety profile of TARE in advanced HCC.
[METHODS] A systematic literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science up to May 2025, following the PRISMA guidelines. Studies comparing TARE with conventional or systemic therapies in advanced HCC were included. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for adverse events (AEs) were calculated using random-effects models. Subgroup and meta-regression analyses explored the influence of study design, liver function (Child-Pugh, ALBI grade), and combined therapies.
[RESULTS] Forty studies encompassing over 10,000 patients were included. TARE significantly improved OS (pooled HR = 0.72, 95% CI 0.63-0.83) and PFS (pooled HR = 0.78, 95% CI 0.69-0.89) compared with controls. Rates of grade ≥3 adverse events were lower in the TARE group (pooled OR = 0.74, 95% CI 0.59-0.93). Subgroup analyses indicated consistent benefits across retrospective and prospective studies, and in patients with Child-Pugh A-B liver function. Meta-regression revealed that younger age and higher objective response rate were associated with improved outcomes.
[CONCLUSION] TARE with Yttrium-90 microspheres confers significant survival benefits and acceptable safety in advanced HCC. These findings support the integration of TARE into multidisciplinary management strategies for advanced HCC, particularly in patients unsuitable for surgical or systemic therapies.
[SYSTEMATIC REVIEW REGISTRATION] PROSPERO (CRD420251163947).
[METHODS] A systematic literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science up to May 2025, following the PRISMA guidelines. Studies comparing TARE with conventional or systemic therapies in advanced HCC were included. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for adverse events (AEs) were calculated using random-effects models. Subgroup and meta-regression analyses explored the influence of study design, liver function (Child-Pugh, ALBI grade), and combined therapies.
[RESULTS] Forty studies encompassing over 10,000 patients were included. TARE significantly improved OS (pooled HR = 0.72, 95% CI 0.63-0.83) and PFS (pooled HR = 0.78, 95% CI 0.69-0.89) compared with controls. Rates of grade ≥3 adverse events were lower in the TARE group (pooled OR = 0.74, 95% CI 0.59-0.93). Subgroup analyses indicated consistent benefits across retrospective and prospective studies, and in patients with Child-Pugh A-B liver function. Meta-regression revealed that younger age and higher objective response rate were associated with improved outcomes.
[CONCLUSION] TARE with Yttrium-90 microspheres confers significant survival benefits and acceptable safety in advanced HCC. These findings support the integration of TARE into multidisciplinary management strategies for advanced HCC, particularly in patients unsuitable for surgical or systemic therapies.
[SYSTEMATIC REVIEW REGISTRATION] PROSPERO (CRD420251163947).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Vascularized iliac crest free flap in maxillofacial reconstruction: Pearls and pitfalls from 437 clinical application.
- The prognostic value of tumor macroscopic morphology in colorectal cancer.
- A pH-Responsive Controlled Release Platform Based on Honeycomb MnO/Carboxymethyl Chitosan/Oxidized Hyaluronic Acid for Multimodal Therapy of Breast Cancer.
- Discovery of 1,2,3,4-Tetrahydrochromeno[3,4-]pyridin-5-one Derivatives as Novel MTHFD Inhibitors for the Treatment of Acute Myeloid Leukemia.
- A cyclometalated iridium(III) complex induces paraptotic cell death via mitochondrial dysfunction and ER stress in triple-negative breast cancer cells.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Efficacy and Safety of Selective Internal Radiation Therapy (SIRT) for Liver Metastases in Breast Cancer: An Umbrella Review.
- Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.
- Traditional Cox regression outperforms large language models in predicting long-term progression of intermediate to advanced hepatocellular carcinoma.
- Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).
- A novel triple-modality approach overcoming prohibitive hepatopulmonary shunt (HPS): Enabling yttrium-90 selective internal radiation therapy (Y90-SIRT) and subsequent curative resection in massive hepatocellular carcinoma (HCC).
- Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.